Seventeen Months, Then One Dollar

On August 17, 2023, the chief executive of a Nasdaq-listed life sciences company put his name to an agreement that priced every share of it at one dollar.

Siddhartha Kadia, today president and chief executive officer of Mesa Laboratories, Inc., was running PhenomeX when Bruker Corporation agreed to buy it outright at $1.00 per share in cash - a total equity value of roughly $108 million. Three years and one month earlier the same business, then trading as Berkeley Lights, had sold 8,100,000 shares to the public at $22.00 each.

Kadia had held the chief executive's chair for seventeen months. He did not preside over the whole descent. He signed at the bottom of it.

That was the line on the record when Mesa's board came looking.

The Ladder Before The Drop

What leads into that signature is not a record of drops. Kadia started at McKinsey & Company in 2001 in the healthcare practice and stayed four years. From 2005 to 2014 he climbed Life Technologies - formerly Invitrogen - running the company's Japan and Greater China businesses, serving as chief marketing officer, and finishing as president of its Life Sciences Division, a $2 billion operation. Thermo Fisher Scientific bought Life Technologies. From 2014 to 2018 he was chief executive of EAG Laboratories, an analytical testing and consulting business; Eurofins Scientific acquired it in December 2017.

He reached Berkeley Lights as a director first, appointed to the board on September 7, 2021 and seated on both the audit and compensation committees. Six months later the board handed him the company.

Seventeen Months, Two Deals

He moved twice, and fast.

On December 21, 2022 Berkeley Lights agreed to acquire IsoPlexis, a Branford, Connecticut rival in single-cell analysis, in an all-stock transaction valued at $57.8 million. IsoPlexis holders received 0.612 Berkeley Lights shares apiece and about 24.8 percent of the combined company. The merged business took a new name and a new ticker: PhenomeX, Nasdaq: CELL. Kadia called it "an important milestone" that "fuels our transformation into a growing, profitable, and sustainable life sciences company." The announcement argued the deal put positive operating cash flow within reach sooner than Berkeley Lights could have managed alone.

Eight months later, Bruker. The tender offer valued the whole of it - the Beacon optofluidic platform, the IsoLight and IsoSpark proteomics instruments, an installed base of more than 400 machines - at about $108 million. "I am very proud of the PhenomeX team," Kadia said in the announcement, "and excited to work with our new colleagues at Bruker as we enter our next phase of growth."

Then the record goes quiet. Mesa's filing places him back in a chief executive's chair in January 2025, at Calibre Scientific, a private supplier of reagents, instruments and consumables to research, diagnostic and biopharmaceutical labs. What he did between August 2023 and January 2025 is not on the public file.

What The Seat Cost

On March 3, 2026 Mesa Laboratories started a leadership transition. Gary Owens, chief executive since 2017, would leave on or about April 13; the filing records that his separation was not the result of any disagreement over the company's operations, policies or practices. The same board action installed Kadia, then 56, after what Mesa described as a comprehensive external search.

The terms are on file. An $850,000 base salary. An annual cash bonus opportunity of at least 100 percent of that. Three million dollars of restricted stock units vesting in equal thirds across three years, and three million dollars of performance share units that can pay anywhere between zero and 200 percent of target.

The changeover was not free. Mesa booked roughly $6.7 million of chief executive transition costs in the quarter ended March 31, 2026 - about $3.7 million of it accelerated stock compensation - against operating income of $2.7 million for that quarter. The board spent more moving the seat than the seat earned in the period.

A Hundred Days, No Speech

On May 27, 2026, six weeks in, Kadia had almost nothing to report. The platform, he offered, has "tremendous potential to create shareholder value while delivering on our promise to Protect the Vulnerable." Guidance would come with the first-half results. That was the whole of it.

The numbers under the sentence were worse than the sentence. Fourth-quarter revenue rose 2.6 percent to $63.7 million, but core organic revenue - the measure that strips out acquisitions and currency - fell 0.6 percent, dragged down by the Biopharmaceutical Development division, where commercial execution faltered and export controls stopped several Peptide systems from shipping at all. For the full year, revenues of $249.1 million grew 3.4 percent and core organic growth was 1.2 percent. Mesa sells into regulated processes that cannot casually switch suppliers, and it was growing at roughly the rate of inflation.

The answer came on August 10. "I joined Mesa about one hundred days ago. I did not spend my time writing a vision statement, I spent it inside the company, with our people and our customers." What he found, he said, was "a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix."

The Division Going Backward

The quarter behind that sentence did most of what he promised. First-quarter revenue of $60.1 million grew 1.0 percent, and core organic growth came back to 0.4 percent - positive, exactly as the company had said it would be. Adjusted operating income excluding unusual items reached 25.6 percent of revenue against 21.7 percent a year earlier. Operating income more than doubled, to $7.0 million. Mesa repaid $8.7 million of debt and cut its total net leverage ratio to 1.85, under the 2.0 target it had set itself.

The complication is in the mix. Calibration Solutions grew 7.6 percent organically. Biopharmaceutical Development, the division that broke in the fourth quarter, grew 5.0 percent. Clinical Genomics was flat. And Sterilization and Disinfection Control - the largest of the four at $24.5 million in the quarter, the one whose backlog clearance had carried the fourth quarter - went backward: down 3.6 percent organic, down 4.6 percent core.

Mesa is spending into it anyway, raising investment in that division through the first half of fiscal 2027 and telling investors to expect margins to moderate toward the mid-twenties as it does. That is the shape of the wager: push profitability down on purpose in the division that is shrinking, and get growth back before the market stops extending credit for it.

What November Owes

He has given the market exactly one date. "In November, alongside first-half results, I will give full-year guidance," Kadia said in August. It will be the first full-year number Mesa puts out under his name, and the first audit of whether the execution problems he called fixable were in fact fixed.

The last agreement he signed as a public-company chief executive put a dollar on the share.